Menna S, Di Virgilio M R, Burke P
Dipartimento Oncologico, Ospedale San Giovanni Antica Sede, Torino.
Radiol Med. 1999 Jun;97(6):472-8.
To define the technique for contrast-enhanced power Doppler US studies of breast lesions and to identify possible clinical applications.
We studied 51 breast lesions detected at mammography and confirmed at cytology and/or surgical biopsy; 15 were benign lesions and 36 carcinomas, namely 14 T1ab, 29 T1c and 8 T2. We found 14 masses with regular margins, 28 with irregular margins, 1 asymmetric density, 2 architectural distortions and 6 clustered calcifications. US studies were performed with an AU5 Harmonic unit (Esaote Biomedica, Genoa, Italy) equipped with a software for online image storage, analysis and automatic quantification of US signal intensity changes after contrast agent injection, namely wash-in and wash-out contrast enhancement curves. The echocontrast agent Levovist (Schering AG, Berlin, Germany), 4.0 g preparation, was administered by i.v. injection (cubital vein) in two times at a concentration of 400 mg/mL. The first 4 mL of Levovist suspension were injected as a bolus at approximately .5 mL/s to evaluate lesion vascularization and choose the best scanning plane for wash-in and wash-out quantification. The remaining 6 mL of Levovist suspension were injected at approximately 1.0 mL/s and dedicated to wash-in and wash-out recording.
The region of interest could not be identified in 2 of 6 calcifications. After Levovist administration, signal enhancement was seen in 36 lesions. Nonsignificant curves were obtained in 7 fibroadenomas, 1 fibrocystic mastopathy and 5 carcinomas. Pathology diagnosed an in situ component around the lesion core (true positives) in 12 carcinomas with perilesional vessels and also 3 more carcinomas with perilesional foci in situ missed at contrast-enhanced US (false negatives). The wash-in/wash-out curves of 30 carcinomas differed from those of the 6 fibroadenomas, in that the former had faster wash-in and an earlier enhancement peak, as well as longer enhancement than the latter. Moreover, fibroadenoma curves are regularly increasing, with moderate variations. As for wash-out, carcinomas exhibited three main patterns, namely a monophasic, a polyphasic and a plateau pattern.
The pattern of enhancement curves in fibroadenomas is related to straight and regular vessels, while arteriovenous shunts in carcinomas cause early signal intensity peaks. Wash-out is longer in carcinomas than in fibroadenomas because the former present anarchic and tortuous vessels with slow flows.
Levovist enhanced US is a complementary test to study known breast lesions which permits the differential diagnosis of carcinomas and fibroadenomas. Our results justify a larger clinical trial to assess the role of this technique for diagnosis, prognosis and staging purposes.
确定乳腺病变对比增强功率多普勒超声检查技术,并确定其可能的临床应用。
我们研究了51例乳腺病变,这些病变经乳腺X线摄影检出,并经细胞学和/或手术活检确诊;其中15例为良性病变,36例为癌,即14例T1ab、29例T1c和8例T2。我们发现14个边缘规则的肿块、28个边缘不规则的肿块、1个不对称密度影、2个结构扭曲影和6个簇状钙化灶。使用配备有用于在线图像存储、分析以及造影剂注射后超声信号强度变化(即注入期和消退期对比增强曲线)自动定量软件的AU5谐波超声仪(意大利热那亚的百胜医疗集团)进行超声检查。静脉注射(肘静脉)4.0 g制剂的超声造影剂声诺维(德国柏林先灵公司),分两次注射,浓度为400 mg/mL。首先以约0.5 mL/s的速度推注4 mL声诺维混悬液以评估病变血管化情况,并选择最佳扫描平面进行注入期和消退期定量分析。其余6 mL声诺维混悬液以约1.0 mL/s的速度注射,并用于注入期和消退期记录。
6个钙化灶中有2个无法确定感兴趣区。注射声诺维后,36个病变出现信号增强。7个纤维腺瘤、1个纤维囊性乳腺病和5个癌获得无显著变化的曲线。病理诊断12例癌在病变核心周围有原位成分(真阳性),且病变周围有血管,另外3例癌在超声造影中漏诊病变周围原位灶(假阴性)。30例癌的注入期/消退期曲线与6个纤维腺瘤的不同,前者注入速度更快,增强峰值出现更早,且增强持续时间比后者更长。此外,纤维腺瘤曲线呈规则上升,变化适中。至于消退期,癌表现出三种主要模式,即单相、多相和平台模式。
纤维腺瘤增强曲线模式与笔直且规则的血管有关,而癌中的动静脉分流导致早期信号强度峰值。癌的消退期比纤维腺瘤长,因为前者存在杂乱且迂曲的血管,血流缓慢。
声诺维增强超声是研究已知乳腺病变的一种补充检查方法,可用于鉴别诊断癌和纤维腺瘤。我们的结果证明有必要进行更大规模的临床试验,以评估该技术在诊断、预后和分期方面的作用。